Factor X and FIXa/FX Bispecific Antibody for Hemophilia A Hemostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia A, such as the use of FIXa/FX bispecific antibodies, face challenges including thromboembolic events, frequent administration requirements, and safety concerns with activated coagulation factors, while traditional hemostatic agents like FVIII preparations or rFVIIa have limitations in efficacy and safety.
Innovation Solution
A pharmaceutical composition combining blood coagulation Factor X with a bispecific antibody that binds to activated blood coagulation Factor IX and Factor X, administered in various schedules to enhance hemostatic efficacy and reduce the risk of thrombosis and inhibitor development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FIXa/FX bisspecific antibody is used for regular prophylactic administration, then hemostatic efficacy is improved and quality of life is enhanced, but thromboembolic events occur and safety concerns arise
Solution Approach 1:
The patent extracts and eliminates the harmful activated Factor VIIa component from the treatment regimen. By using only the FIXa/FX bispecific antibody without combining it with activated Factor VIIa, the invention removes the source of thrombotic complications while preserving the hemostatic efficacy provided by the bispecific antibody alone
Solution Approach 2:
The invention converts the potentially harmful combination therapy into a safe monotherapy approach. By administering the FIXa/FX bisspecific antibody as a single agent rather than in combination with other activated coagulation factors, the treatment transforms a high-risk regimen into a safe and effective therapy that avoids thromboembolic events
2Reliability
If rFVIIa preparation is administered to hemophilia A patients with inhibitors, then hemostatic effect is achieved, but frequent administration is required which imposes burden on patients and healthcare professionals
Solution Approach 1:
The patent utilizes the long half-life characteristics of the FIXa/FX bisspecific antibody to enable dynamic dosing intervals of one week or longer. This contrasts with the static frequent dosing required for rFVIIa, allowing patients to receive treatment less frequently while maintaining effective hemostatic coverage throughout the dosing interval
Solution Approach 2:
The invention implements periodic administration of the FIXa/FX bisspecific antibody at extended intervals (one week or longer between doses). This periodic dosing strategy maintains therapeutic efficacy while significantly reducing the administrative burden compared to the frequent dosing required for short-half-life agents like rFVIIa
3Reliability
If FVIII preparation is administered to hemophilia A patients without inhibitors, then hemostatic effect is achieved, but risk of inducing FVIII inhibitors occurs
Solution Approach 1:
The FIXa/FX bisspecific antibody serves as an intermediary mechanism that achieves hemostatic effect through a different pathway than direct FVIII replacement. By activating both Factor IX and Factor X simultaneously, the bispecific antibody promotes thrombin generation without requiring FVIII administration, thereby eliminating the risk of FVIII inhibitor formation while maintaining effective hemostasis
4Adaptability or versatility
If Factor IX preparation is used as hemostatic agent, then treatment option is provided, but effect in promoting thrombin generation is weaker compared to Factor X preparation
Solution Approach 1:
The patent merges the functions of Factor IX and Factor X activation into a single bispecific antibody molecule. The FIXa/FX bisspecific antibody simultaneously activates both coagulation factors, combining the thrombin generation promotion effects of both pathways into one therapeutic agent, thereby achieving superior thrombin generation compared to Factor IX preparation alone
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly improves thrombin generation, clot formation, and reduces bleeding frequency, offering a safer and more effective treatment for hemophilia A patients with or without inhibitors, with a longer dosing interval and reduced risk of thrombosis.
Implementation Method 1
a bispecific antibody that binds to activated blood coagulation Factor IX and blood coagulation Factor X
Implementation Method 2
blood coagulation Factor X is used in combination with a bisspecific antibody that binds to activated blood coagulation Factor IX and blood coagulation Factor X
Data Source
Figure 1
Figure 2
Figure 3(A)~3(B)
AI summary
Provided is a pharmaceutical composition comprising blood coagulation Factor X for treating a subject with hemophilia A. The present invention relates to a pharmaceutical composition comprising blood coagulation Factor X for treating a subject with hemophilia A, wherein the blood coagulation Factor X is used in combination with a bispecific antibody binding to activated blood coagulation Factor IX and blood coagulation Factor X.